Efficacy and safety of sequential use of everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with bevacizumab (BEV) with or without interferon (INF) therapy: Overall survival (OS) result from the European AVATOR retrospective study.
Antoine Thiery-Vuillemin
Research Funding - Novartis; Pfizer
Expert Testimony - Novartis; Pfizer
Other Remuneration - Bayer; Novartis; Pfizer; Roche
Christine Theodore
No relevant relationships to disclose
Lutz Jacobasch
No relevant relationships to disclose
Jorg Schmitz
No relevant relationships to disclose
Aline Guillot
Research Funding - Novartis
Other Remuneration - Novartis
Christos Papandreou
No relevant relationships to disclose
Christos E. Emmanouilides
Research Funding - Novartis
Stefano Chong Hun Kim
No relevant relationships to disclose
Meryem Ktiouet
Employment or Leadership Position - Novartis
Nadia Kelkouli
Employment or Leadership Position - Novartis
Thierry Nguyen
Honoraria - Novartis